Enfortumab vedotin

维恩妥尤单抗

Report date: 2026/05/15 20:01:45
First In Class

Base Information

Drug NameEnfortumab vedotin
Drug Alias Nameenfortumab vedotin-ejfvEnfortumabPadcev备思复DLE8519RWM +[13] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionTubulin polymerisation inhibitorsAnti-NECTIN4
TargetsNectin-4Tubulin
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsUrethral Neoplasms +[17] 
Global Approved IndicationsCarcinoma, Transitional Cell
Approved Indications in ChinaCarcinoma, Transitional Cell
Original Approved Country/TerritoryUnited States
Original Approved Date2019/12/18
Country/TerritoryCzechiaBelgiumCanada +[37] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAgensys IncSeagen Inc
China Registration ClassN/A

Develop Information

Active CompaniesUtah State UniversityAstellas Pharma Us IncUniversity of Texas Southwestern Medical Center +[14] 
Inactive CompaniesAstellas (China) Investment Co LtdAgensys IncAstellas Pharma Hong Kong Company Ltd
Active IndicationsSolid tumoursUrinary Bladder NeoplasmsUrethral Neoplasms +[15] 
Inactive IndicationsCarcinoma in SituNeoplasms

Other Information

ATC CodeL01XC
Related LinksWikipediaDrugBankKEGG